PBMEF Indicators

Are you on a successful path to ending tuberculosis (TB)? This group of indicators will help you answer that question by providing standardized comparisons across the United States Agency for International Development’s (USAID’s) TB priority countries. These indicators are intended to help measure each outcome and impact; help decision-makers answer questions; and measure progress towards global and individual country targets.

Contains example visualizations with real data.

Core Indicators

Reach

[PR-1] Private Sector TB Notifications

[RN-1] Drug-Resistant TB Notifications

[CI-1] Contact Investigation Coverage

[DT-3] TB Case Detection Rate or TB Treatment Coverage

[DT-12] Bacteriological Diagnosis Coverage (Pulmonary TB)

[CH-5] Childhood TB Notifications

Cure

[RS-1] Drug-Resistant TB Treatment Success Rate

[SS-1] TB Treatment Success Rate

Prevent

[PT-1] Number of Individuals Started on TB Preventive Treatment (TPT)

Sustain

[SN-1] Percent of TB Financing Expected from Domestic Sources

Extended Indicators

Active Case Finding (AF)

[AF-1] Number of Individuals Eligible for Screening

[AF-2] Number of Individuals Screened for TB

[AF-3] Screening Coverage among Risk Groups

[AF-4] Number of Presumptive TB Cases Identified

[AF-5] Number of Presumptive TB Cases Tested for TB

[AF-6] Number of Presumptive TB Cases with Confirmed TB

[AF-8] Number Needed to Test to Find One TB Case

[AF-9] Number with Confirmed TB Starting Appropriate Treatment

Show More Show Less

Childhood TB (CH)

[CH-13] Childhood (Ages 0-14) DR-TB Notifications

[CH-14] Treatment Success Rate for Childhood TB (Ages 0-14)

[CH-15] Treatment Success Rate for Childhood TB (Ages 0-4)

[CH-16] Treatment Success Rate for Childhood TB (Ages 5-14)

[CH-17] Treatment Outcome for Childhood TB (Ages 0-14): Died

[CH-18] Treatment Outcome for Childhood TB (Ages 0-14): Treatment Failed

[CH-19] Treatment Outcome for Childhood TB (Ages 0-14): Lost to Follow-up (LTFU)

[CH-2] Estimated Number of TB Deaths among 0-to-14-year-old Children

[CH-20] Treatment Outcome for Childhood TB (Ages 0-14): Not Evaluated

[CH-3] Children (0-14 years) Clinically Evaluated for TB

[CH-21] Number of Childhood DR-TB (Ages 0-14) Who Were Enrolled on Appropriate DR-TB Treatment by Regimen during a Specified Period

[CH-6] Percentage of New and Relapse TB Case Notifications That Are among 0-14-year-old Children, Calculated at National and Subnational Level

[CH-22] Childhood DR-TB (Ages 0-14) Treatment Success Rate

[CH-7] Childhood TB Detection

[CH-23] Childhood DR-TB (Ages 0-14) Treatment Outcome: Died

[CH-8] Childhood TB (0-4) Notifications

[CH-26] Childhood DR-TB Treatment Outcome: Not Evaluated

[CH-9] Childhood TB (5-14) Notifications

[CH-27] Use of Child-friendly Formulations for TB Treatment, First-line Drugs (Yes/No)

[CH-10] Ratio of 0-4 to 5-14 years-old Notifications

[CH-28] Use of Child-friendly Formulations for TB Treatment, Second-line Drugs (Yes/No)

[CH-11] Percent of Notified New and Relapse Pulmonary TB Notifications (0-14 years-old) with Bacteriological Confirmation

[CH-29] Stockouts of Child-friendly Formulations for TB Treatment, by Year and Length of Stockout

[CH-12] Percent of Notified New and Relapse Extrapulmonary TB Notifications (0-14 years-old) with Bacteriological Confirmation

Show More Show Less

Contact Investigation (CI)

[CI-5] Percent of Contacts Detected with DR-TB Disease through Contact Investigation of DR-TB Index Case

[CI-6] Percent of Contacts Detected with DS-TB Disease through Contact Investigation of DR-TB Index Case

[CI-7] Percent of Close Contacts who Tested Positive for TBI

[CI-8] Percent of Eligible Index Cases with Contact Investigations Conducted

[CI-9] Percent of Identified Contacts Investigated

[CI-10] Percent of Referred Contacts who Completed Evaluation

[CI-12] Contacts Screened Negative for TB

[CI-2] Estimated Average Number of Household Contacts Identified per One Notified New and Relapse Bacteriologically Confirmed Pulmonary TB Case

[CI-3] Percent of Contacts Evaluated for TB Disease

[CI-4] Percent of Contacts Detected with TB Disease

Show More Show Less

Drug-Resistant TB Notifications (RN)

[RN-3] Percent of Notified RR/MDR-TB Cases with DST Results for Second-line TB Drugs

[RN-4] Number of DR-TB Enrolled on Treatment

[RN-5] DR-TB Treatment Enrollment Coverage

[RN-6] Number of Treatment Sites Providing DR-TB Treatment

[RN-7] Number of DR- TB initiated on "all oral" short treatment regimen

[RN-8] Number of DR- TB initiated on "all oral" longer treatment regimen

Drug-Resistant TB Treatment Success (RS)

[RS-2] DR-TB Treatment Outcome: Died

[RS-3] DR-TB Treatment Outcome: Treatment failed

[RS-4] DR-TB Treatment Outcome: LTFU

[RS-5] Drug-resistant TB Treatment Outcome: Not evaluated

[RS-6] Number of Patients on DR-TB Treatment Who Had Adverse Events Registered in the Reporting Year

[RS-7] Percent of DR-TB Patients Who Receive DR-TB Care Package

Healthcare Worker Screening (HW)

[HW-1] Percentage of HCWs Screened for TB

[HW-2] Percentage of HCWs Screened Positive for TB

[HW-3] Percentage of HCWs Diagnosed with TB Disease

[HW-4] HCWs Who Were Ruled Out for TB Disease

[HW-5] Percentage of HCWs Tested for TBI

[HW-6] Percentage of HCWs Tested Positive for TBI among HCWs

[HW-8] PLHIV: HCWs Who Were Ruled Out for TB Disease, are PLHIV, and Were Initiated on TPT

[HW-9] Contacts: HCWs Who Were Ruled Out for TB Disease, and Are Eligible Household Contacts

[HW-10] Contacts: HCWs Who Were Ruled Out for TB Disease, Are Eligible Household Contacts, and Were Initiated on TPT

[HW-11] TBI-positive: HCWs Who Were Ruled Out for TB Disease, and Are Neither PLHIV nor Eligible HH Contacts, and Tested Positive for TBI during the Reporting Period

[HW-12] TBI-positive: HCWs Who Were Ruled Out for TB Disease, Are Neither PLHIV nor Eligible Household Contacts, Tested Positive for TBI and Were Initiated on TPT

[HW-13] HCWs Who Completed TPT

Show More Show Less

Presumptive TB (PS)

[PS-1] Number of Individuals Screened for TB at Healthcare Facilities

[PS-2] Number of Presumptive TB Patients Identified

[PS-3] Number of Presumptive TB Patients with Completed Evaluation for TB Disease

[PS-4] Number of Presumptive TB Patients Diagnosed with TB Disease

[PS-5] Number of Presumptive TB Patients Who Were Ruled Out for TB Disease and Tested for TBI

[PS-6] Presumptive TB Patients Tested Positive for TBI

[PS-8] Number of Health Facilities Reporting on Number of Presumptive TB Patients during the Reporting Period

Show More Show Less

Prevention (PV)

[PV-2] Number of Contacts of Bacteriologically Confirmed Pulmonary TB Cases who Were Screened for TB Infection (and/or Tested for TBI) According to National Screening Protocols during the Specified Reporting Period

[PV-3] Number of Eligible (Ruled Out for TB Disease) Individuals Who Started Treatment for TB Infection during the Reporting Year

[PV-4] Number of Individuals Who Completed Treatment for TBI during the Reporting Period

[PV-1] Number of Individuals Screened for TB Disease and TBI Outside of Health Facilities by Community Health Worker or Other Qualified Person (According to National Screening Protocols) during the Specified Reporting Period

Private Sector (PR)

[PR-3] Percentage of Privately Notified Pulmonary Cases with Bacteriologically Confirmed TB

[PR-4] Percentage of Notified DR-TB Cases Contributed by Private Sector

[PR-5] Percentage of Privately Notified Pulmonary Cases with Confirmed Result on Rifampicin Sensitivity

[PR-6] Treatment Success Rate of TB Cases Notified by Private Sector

[PR-7] Treatment Success Rate of DR-TB Cases Enrolled on Treatment in Private Sector

[PR-2] Percentage of Notified TB Cases Contributed by Private Sector

Sustainability (SN)

[SN-2] Total Funding Received for TB

[SN-16] Non-admission to Initiate DR-TB Treatment

[SN-30] Anti DR-TB Drug Availability for Patients for Free

[SN-39] Inclusiveness of Civil Society/TB Survivors

[SN-43] Stockout of Second-line TB Treatment Drugs

[SN-3] Percent of TB Financing Received from Domestic Sources

[SN-31] TB Training Module/Guidance Contain Information on Human Rights Issues

[SN- 39A] A – NTP Consults with TB Civil Society/TB Survivors to Review Progress

[SN-44] Stockout of TB Diagnostic Products

[SN-4] Domestic Funding for Drugs

[SN-18] TB Screening

[SN-32] TB Stigma Reduction

[SN- 39B] B – NTP Invites TB Civil Society/TB Survivors to Participate in JPR/JMM/External Reviews

[SN-45] First-line TB Treatment Drugs Past Expiration

[SN-5] Domestic Funding for Lab Commodities

[SN-19] TBI TPT

[SN-33] Approval Process Efficiency

[SN- 39C] C – NTP Consults with Civil Society and TB Survivors to Develop the NSP and Donor Proposals

[SN-46] Second-line TB Treatment Drugs Past Expiration

[SN-6] Capacity of NTP for Absorption of Domestic Funding (In Reporting Year)

[SN-20] Regimen for TBI

[SN- 33A] Approval Process Efficiency – A

[SN- 39D] D – Civil Society/TB Survivors Involved in TB Research Development/Planning, Implementation, and Dissemination

[SN-47] Replenishable TB Diagnostic Products Past Expiration

[SN-7] Capacity of NTP for Absorption of Funds from GF

[SN-21] NTP Ownership of Tools for Public Visibility

[SN- 33B] Approval Process Efficiency-B

[SN-40] Inclusiveness of Community (Not Organized) and Subnational Entities

[SN-48] Stockouts of Child-friendly Formulations for TB Treatment

[SN-8] Social Protection

[SN-22] Case Notification Data Publicly Available on NTP Website/MOH

[SN-34] NTP Manager Empowerment in the Organizational Hierarchy

[SN- 40A] Community (Not Organized) Feedback Obtained

[SN-8A] Social Protection Scheme Available

[SN-23] TB Technical Guidelines Publicly Available on the NTP Website/MOH

[SN-35] NTP Capacity

[SN- 40B] Subnational Government Entities Feedback Obtained

[SN-8B] Availability of Social Health Insurance System Covering TB in the Country

[SN-24] TB NSP Publicly Available on the NTP Website/Web Page

[SN-36] Effective NTP Capacity

[SN-41] Inclusiveness of Gender

[SN-9] Percent of TB Patients Covered by Insurance

[SN-25] Annual Budget of NTP is Publicly Available

[SN- 36A] Effective NTP Capacity in Relation to Population

[SN- 41A] A – NTP Staff Undertake TB and Gender Sensitization/Training

[SN-10] Catastrophic Costs Related to TB Care

[SN-26] Status of TB Joint Program Review (JPR) or Joint Monitoring Mission (JMM)

[SN- 36B] Effective NTP Capacity in Relation to TB Burden

[SN- 41B] B – Male-Female Ratio of NTP and Provincial Managers

[SN-11] Use of Rapid Molecular Diagnostic Testing (WHO-recommended Rapid Test) WRD

[SN- 26A] JPR/JMM was Conducted Recently

[SN- 36C] Effective NTP Capacity in Relation to Number of Provinces

[SN- 41C] C – TB Gender Assessment Report

[SN-12] Universal DST

[SN- 26B] Availability of Final JPR/JMM Report

[SN-37] Social Contracting with Govt. Funds (NGOs/ Private Sector)

[SN- 41D] D – NSP Highlights Gender Inclusiveness in TB Services and Programs

[SN-13] New WHO DR-TB Treatment Guidelines

[SN-27] Partnership Statement Adoption and Implementation

[SN- 37A] A – Inclusiveness of NGOs in Social Contracting

[SN- 41E] E – Women TB Survivors Included in any NTP Event in Reporting Year

[SN-14] Pediatric TB Treatment

[SN-28] Mandatory Notification

[SN- 37B] B – Inclusiveness of Private Sector in Social Contracting

[SN- 41F] F – Gender Disaggregated Data for Treatment Outcome Available for Most Recent Reported Cohort

[SN-15] Self-administered DS-TB Treatment

[SN-29] Anti DR-TB Drugs Listed on the Country’s National Essential Medicines List (NEML)

[SN-38] Inclusiveness of Key Populations (KPs)

[SN-42] Stockout of First-line TB Treatment Drugs

Show More Show Less

TB Detection (DT)

[DT-1] TB Case Notifications

[DT-19] Percent of Rifampicin Monoresistance (Previously Treated Including Relapse)

[DT-2] TB Case Notification Rate (CNR)

[DT-20] Percent of Rifampicin Monoresistance (New and Previously Treated Including Relapse)

[DT-4] Percent of Extrapulmonary TB Cases Notified

[DT-21] TB Patients with Available DST Results for Isoniazid and Rifampicin

[DT-22] TB Patients with Test Results for Rifampicin and Isoniazid and with Resistance to Isoniazid

[DT-6] Number of Notified Extrapulmonary TB (New and Relapse) Clinically Diagnosed

[DT-23] TB Patients with Test Results for Rifampicin and Isoniazid and with Resistance to Rifampicin

[DT-7] Number of Facilities Reporting Extrapulmonary TB Cases

[DT-24] TB Patients with Resistance to Both Isoniazid and Rifampicin (DR-TB)

[DT-8] Percent of Total Cases Notified that Were Referred or Diagnosed Via Community-based Approaches (Outside of Health Facilities) in the Basic Management Units with Data on Referrals by Community Health Workers

[DT-25] Percent of New TB Patients with INH Monoresistance

[DT-34] Percent of Rapid Diagnostic Testing of New and Relapse TB Cases

[DT-9] Percent of Prisons Conducting Regular Screening for TB According to National Policy

[DT-26] Percent of INH Monoresistance (Previously Treated Including Relapse)

[DT-10] Percent of Prisons Conducting Screening for TB with Chest X-ray

[DT-27] Percent of Total INH Monoresistance (New and Previously Treated Including Relapse)

[DT-11] Percent of Health Facilities Implementing Intensified Case Finding (i.e., Using Standard of Practice)

[DT-28] Number of Laboratory-confirmed TB Cases That Are Resistant to Rifampicin and Resistant to Any Fluoroquinolone (pre-XDR-TB or XDR-TB)

[DT-13] Percent of WHO-recommended Rapid Diagnostic (WRD) Testing Sites that Are Included in a Quality Assurance Program

[DT-29] Proportion of Presumptive TB Patients Identified during the Reporting Period with Specimen Collected within Specified Target Timeframe

[DT-14] Rapid Diagnostic Testing Coverage

[DT-30] Proportion of Specimens Collected during the Reporting Period Submitted to Testing Laboratory within Specified Target Timeframe

[DT-15] Rapid Diagnostic Testing of New and Relapse TB Cases

[DT-31] Proportion of Specimens Received at Testing Facility and Tested during the Reporting Period within Specified Target Timeframe

[DT-16] TB Patients with Test Results for Rifampicin

[DT-32] Proportion of Specimens Tested and Results Report to Referring Facility (or Physician) during the Reporting Period within Specified Target Timeframe

[DT-17] TB Patients with Resistance to Rifampicin (RR-TB)

[DT-33] Proportion of Results Reported and Patients Initiated on Treatment during the Reporting Period within Specified Target Timeframe

[DT-18] Percent of New TB Patients with Rifampicin Monoresistance

Show More Show Less

TB Preventive Treatment (PT)

[PT-2] Number of Household Contacts Started on TPT

[PT-3] Number of Children (< 5 Years) Household Contacts Started on TPT

[PT-4] Number of Adult Household Contacts and Contacts > 5 Years Started on TPT

[PT-5] Number of PLHIV Started on TPT

[PT-6] Percent of Household Contacts Started on TPT

[PT-7] Percent of Children (< 5 years) Household Contacts Started on TPT

[PT-10] Percent of Children (< 5 Years) Household Contacts Completed TPT

[PT-11] Percent of Adult Household Contacts (and Contacts > 5 Years) Completed TPT

[PT-12] Percent of PLHIV Completed TPT

[PT-13] Percent TPT Patients LTFU

[PT-14] Percent TPT Patients Interrupted Due to ADR

[PT-15] Percent TPT Patients Developed TB during TPT

[PT-16] Percent TPT Patients with Baseline AST/ALT Tests

Show More Show Less

TB Treatment Success (SS)

[SS-2] TB Treatment Outcome: Died during Treatment

[SS-3] TB Treatment Outcome: Treatment Failed

[SS-4] TB Treatment Outcome: LTFU

[SS-5] TB Treatment Outcome: Not Evaluated

[SS-7] Percent of DS-TB patients who receive TB care package

TB/HIV (TH)

[TH-1] Percent of PLHIV Enrolled on ART Screened for TB Disease

[TH-16] Percent of DR-TB Patients Recorded as HIV-positive

[TH-30] PLHIV with TB who have viral load testing every 6 months

[TH-2] Percent of PLHIV Enrolled on ART, Screened Positive for TB Disease

[TH-17] Percent of DR-TB/HIV Coinfected Patients Enrolled on Appropriate DR-TB Treatment

[TH-3] Percent of PLHIV Enrolled on ART, Tested for TB Disease

[TH-4] Percent of PLHIV Enrolled on ART Who Tested Positive for TB Disease

[TH-19] Percent of HIV-positive DR-TB Patients Started or Continued on ART

[TH-5] Percent of PLHIV Enrolled on ART and Tested Positive for TB Disease, Who Were Enrolled on TB Treatment

[SS-6] Treatment Success Rate for TB/HIV Coinfected Patients

[TH-6] Percent of PLHIV Enrolled on ART, Screened Negative for TB Disease

[TH-20] TB/HIV Coinfected Treatment Outcome: Died during Treatment (Expressed as Percentage)

[TH-7] Percent of PLHIV Enrolled on ART, Tested for TBI

[TH-21] TB/HIV Coinfected Treatment Outcome: Treatment Failed

[TH-8] Percent of PLHIV Enrolled on ART, Tested Positive for TBI

[TH-22] TB/HIV Coinfected Treatment Outcome: LTFU

[PT-8] Percent of PLHIV Started on TPT

[TH-23] TB/HIV Coinfected Treatment Outcome: Not Evaluated

[TH-9] Percent of PLHIV on TPT: LTFU

[RS-8] Treatment Success Rate for DR-TB/HIV Coinfected Patients

[TH-10] Percent of PLHIV on TPT Developed TB during TPT

[TH-24] DR-TB/HIV Coinfection Treatment Outcome: Died during Treatment (Expressed as Percentage)

[TH-11] Percent of PLHIV on TPT, and TPT Interrupted due to Adverse Drug Reaction (ADR)

[TH-25] DR-TB/HIV Coinfected Treatment Outcome: Treatment Failed

[TH-12] Percent of PLHIV on TPT, with Baseline AST/ALT Tests

[TH-26] DR-TB/HIV Coinfected Treatment Outcome: LTFU

[TH-13] Percent of TB Patients with Known HIV Status

[TH-27] DR-TB/HIV Coinfected Treatment Outcome: Not Evaluated

[TH-14] Percent of TB Patients Recorded as HIV-positive

[TH-28] PLHIV with TB Who Have CD4 > 100

[TH-15] Percent of DR-TB Patients with Known HIV Status

[TH-29] PLHIV with TB Who Have CD4 > 350

Show More Show Less